查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1580001

脉络膜新生血管市场：按产品类型、治疗类型、疾病类型、最终用户划分 - 全球预测 2025-2030

Choroidal Neovascularization Market by Product Type (Biologics, Devices, Drugs), Treatment Type (Anti-VEGF Drugs, Laser Photocoagulation, Photodynamic Therapy), Disease Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

脉络膜新生血管市场2023年估值为59.5亿美元，预计到2024年将达到63.8亿美元，复合年增长率为7.57%，到2030年达到99.3亿美元。

脉络膜新生血管（CNV）是眼球脉络膜层新血管的形成，通常会导致严重的视力障碍和老龄化黄斑部病变（AMD）等疾病。随着世界老化导致 AMD 盛行率增加，对创新治疗方法的需求推动了 CNV 治疗市场的发展。目前的治疗方法包括抗 VEGF（血管内皮生长因子）疗法、雷射疗法和动态疗法，最终用户包括眼科诊所、医院和眼科专科医疗中心。市场成长受到药物输送系统的进步、患者意识的提高以及专注于提高治疗效果的持续研究的影响。此外，技术创新，特别是生技药品和基因治疗领域的技术创新，为公司扩大产品系列提供了重要机会。然而，治疗成本上升、监管障碍和潜在副作用等挑战需要持续的研究和创新，以确保更有效和负担得起的解决方案。

主要市场统计
基准年[2023] 59.5亿美元
预测年份 [2024] 63.8亿美元
预测年份 [2030] 99.3亿美元
复合年增长率（%） 7.57%

关键的商机在于开发缓释性和个人化医疗，利用遗传标记制定个人化治疗计画。公司可以投资合作研究，探索新的作用机制和联合治疗，进而改善患者的治疗效果。儘管存在这些治疗机会，但市场仍面临抗治疗性和 CNV 病理生理学复杂性等限制，这使得通用治疗方法的开发变得复杂。此外，经济因素和获得医疗保健的问题对市场渗透提出了挑战，特别是在低收入地区。具有高潜力的创新领域包括用于优化治疗通讯协定的人工智慧辅助诊断，以及旨在精确靶向 CNV 组织并减少对周围眼部结构的附带损害的人工智慧辅助诊断以及奈米技术增强的药物传输系统。为了发展您的业务，专注于与研究机构合作并积极参与全球临床试验，以获得对新趋势和技术的宝贵见解，并与动态发展的市场保持联繫，这有助于企业在竞争中保持竞争力。

市场动态：快速发展的脉络膜新生血管市场的关键市场洞察

供需的动态交互作用正在改变脉络膜新生血管市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 在高龄化社会中，老龄化黄斑部病变（AMD）和相关疾病的盛行率不断增加
    • 提高早期诊断和治疗意识
  • 市场限制因素
    • 由于治疗费用上涨导致可近性下降
  • 市场机会
    • 利用人工智慧利用视网膜影像进行早期诊断
    • 开发缓释性植入和注射以减少治疗次数
  • 市场挑战
    • 与目前治疗相关的可能的副作用和併发症

波特五力：开拓脉络膜新生血管市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解脉络膜新生血管市场的外部影响

外部宏观环境因素在塑造脉络膜新生血管市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解脉络膜新生血管市场的竞争状况

对脉络膜新生血管市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵脉络膜新生血管市场供应商的绩效评估

FPNV定位矩阵是评估脉络膜新生血管市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製脉络膜新生血管市场的成功之路

对脉络膜新生血管市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 在高龄化社会中，老龄化黄斑部病变（AMD）和相关疾病的盛行率不断增加
      • 提高早期诊断和治疗意识
    • 抑制因素
      • 治疗费用高且取得机会有限
    • 机会
      • 利用人工智慧利用视网膜影像进行早期诊断
      • 开发缓释植入和注射以减少治疗频率
    • 任务
      • 与目前治疗方法相关的潜在副作用和併发症
  • 市场区隔分析
    • 产品类型：针对性的作用机制和功效正在增加对生物製药的偏好。
    • 最终用户：可用的治疗选择范围广泛，包括雷射疗法、抗 VEGF 注射和动态疗法，正在增加医院的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章脉络膜新生血管市场：依产品类型

  • 生物製药
  • 装置
  • 药物

第七章依治疗类型分類的脉络膜新生血管市场

  • 抗VEGF药物
  • 雷射光凝
  • 动态疗法

第八章脉络膜新生血管市场：依疾病类型

  • 类型1
  • 2型
  • 类型3

第九章脉络膜新生血管市场：依最终用户分类

  • 医院
  • 眼科诊所
  • 调查机构

第10章美洲脉络膜新生血管市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区脉络膜新生血管市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲脉络膜新生血管市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Biocon Biologics 旨在透过 FDA核准Yesafili 来扩大市场，Yesafili 是一种与阿柏西普相容的眼科生物仿製药。
    • 参天製药和拜耳製药在日本推出了 Eylea 8mg，这是一种高浓缩製剂，可改善 nAMD 和 DME 的治疗。
    • 山德士以 1.7 亿美元从 Coherus Biosciences 收购生物相似药雷珠单抗 CIMERLI，加强其在眼科市场的影响力和产品组合
  • 战略分析和建议

公司名单

  • Adverum Biotechnologies
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch+Lomb Corporation
  • Bausch Health
  • Bayer AG
  • Biogen, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Clearside Biomedical
  • F. Hoffmann-La Roche Ltd.
  • Genentech USA, Inc.
  • Genentech, Inc.
  • Iveric Bio
  • Kodiak Sciences
  • Kodiax Pharmaceuticals
  • Novartis AG
  • PulseSight Therapeutics
  • Regeneron Pharmaceuticals Inc.
  • Samsung Bioepis.
  • Sandoz Inc.
  • Santen Pharmaceutical Co. Ltd.
Product Code: MRR-976C0ED91BDE

The Choroidal Neovascularization Market was valued at USD 5.95 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 9.93 billion by 2030.

Choroidal Neovascularization (CNV) involves the formation of new blood vessels in the choroid layer of the eye, often linked to severe vision impairment and conditions like age-related macular degeneration (AMD). The market for CNV treatment is driven by the necessity for innovative therapeutic approaches due to the rising prevalence of AMD among aging populations globally. Current applications include anti-VEGF (vascular endothelial growth factor) therapies, laser treatment, and photodynamic therapy, with end-users spanning ophthalmology clinics, hospitals, and specialized eye care centers. Market growth is influenced by advancements in drug delivery systems, increasing patient awareness, and ongoing research focused on improving treatment efficacy. Moreover, technological innovations, particularly in biologics and gene therapy, present significant opportunities for companies to expand their product portfolios. However, challenges such as the high cost of treatments, regulatory hurdles, and potential side effects necessitate continuous research and innovation to ensure more effective and affordable solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 5.95 billion
Estimated Year [2024] USD 6.38 billion
Forecast Year [2030] USD 9.93 billion
CAGR (%) 7.57%

Key opportunities lie in the development of sustained-release drug formulations and personalized medicine, leveraging genetic markers for individualized treatment plans. Companies could invest in collaborative research efforts to explore novel mechanisms of action and combination therapies that could enhance patient outcomes. Despite these opportunities, the market faces limitations such as treatment resistance and the complexity of CNV pathophysiology, which complicates the development of universal treatments. Additionally, economic factors and healthcare accessibility issues pose challenges to market penetration, particularly in low-income regions. Areas of innovation with high potential include AI-assisted diagnostics to optimize treatment protocols, and nanotechnology-enhanced drug delivery systems designed to target CNV tissues precisely and reduce collateral damage to surrounding eye structures. For business growth, focusing on partnerships with research institutions and actively participating in global clinical trials can provide valuable insights into emerging trends and technologies, helping firms remain competitive in a dynamic and evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Choroidal Neovascularization Market

The Choroidal Neovascularization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
    • Enhanced awareness about early diagnosis and treatment
  • Market Restraints
    • High cost of treatment limiting the accessibility
  • Market Opportunities
    • Leveraging artificial intelligence for early diagnosis using retinal imaging
    • Developing sustained-release implants and injections for reducing the frequency of treatments
  • Market Challenges
    • Potential side effects and complications associated with current treatments

Porter's Five Forces: A Strategic Tool for Navigating the Choroidal Neovascularization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Choroidal Neovascularization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Choroidal Neovascularization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Choroidal Neovascularization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Choroidal Neovascularization Market

A detailed market share analysis in the Choroidal Neovascularization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Choroidal Neovascularization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Choroidal Neovascularization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Choroidal Neovascularization Market

A strategic analysis of the Choroidal Neovascularization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Choroidal Neovascularization Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Bausch + Lomb Corporation, Bausch Health, Bayer AG, Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Clearside Biomedical, F. Hoffmann-La Roche Ltd., Genentech USA, Inc., Genentech, Inc., Iveric Bio, Kodiak Sciences, Kodiax Pharmaceuticals, Novartis AG, PulseSight Therapeutics, Regeneron Pharmaceuticals Inc., Samsung Bioepis., Sandoz Inc., and Santen Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Choroidal Neovascularization Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Biologics, Devices, and Drugs.
  • Based on Treatment Type, market is studied across Anti-VEGF Drugs, Laser Photocoagulation, and Photodynamic Therapy.
  • Based on Disease Type, market is studied across Type 1, Type 2, and Type 3.
  • Based on End-User, market is studied across Hospitals, Ophthalmology Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
      • 5.1.1.2. Enhanced awareness about early diagnosis and treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment limiting the accessibility
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging artificial intelligence for early diagnosis using retinal imaging
      • 5.1.3.2. Developing sustained-release implants and injections for reducing the frequency of treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Potential side effects and complications associated with current treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product type: Increasing preference for biologics due to their targeted mechanism of action and efficacy.
    • 5.2.2. End-user: Increasing need in hospitals due to presence of a wide range of treatment options, including laser therapy, anti-VEGF injections, and photodynamic therapy.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Choroidal Neovascularization Market, by Product Type

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Devices
  • 6.4. Drugs

7. Choroidal Neovascularization Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Anti-VEGF Drugs
  • 7.3. Laser Photocoagulation
  • 7.4. Photodynamic Therapy

8. Choroidal Neovascularization Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Type 1
  • 8.3. Type 2
  • 8.4. Type 3

9. Choroidal Neovascularization Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Ophthalmology Clinics
  • 9.4. Research Institutes

10. Americas Choroidal Neovascularization Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Choroidal Neovascularization Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Choroidal Neovascularization Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Biocon Biologics receives FDA approval for Yesafili, an ophthalmology biosimilar interchangeable with aflibercept, targeting market growth
    • 13.3.2. Santen Pharmaceutical and Bayer Yakuhin launched Eylea 8mg in Japan to improve nAMD and DME treatment with higher concentration formula
    • 13.3.3. Sandoz USD 170 million acquisition of biosimilar ranibizumab CIMERLI from Coherus BioSciences bolsters ophthalmology market presence and portfolio
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adverum Biotechnologies
  • 2. Apellis Pharmaceuticals, Inc.
  • 3. Astellas Pharma Inc.
  • 4. Bausch + Lomb Corporation
  • 5. Bausch Health
  • 6. Bayer AG
  • 7. Biogen, Inc.
  • 8. Chugai Pharmaceutical Co., Ltd.
  • 9. Clearside Biomedical
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech USA, Inc.
  • 12. Genentech, Inc.
  • 13. Iveric Bio
  • 14. Kodiak Sciences
  • 15. Kodiax Pharmaceuticals
  • 16. Novartis AG
  • 17. PulseSight Therapeutics
  • 18. Regeneron Pharmaceuticals Inc.
  • 19. Samsung Bioepis.
  • 20. Sandoz Inc.
  • 21. Santen Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. CHOROIDAL NEOVASCULARIZATION MARKET RESEARCH PROCESS
  • FIGURE 2. CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHOROIDAL NEOVASCULARIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHOROIDAL NEOVASCULARIZATION MARKET DYNAMICS
  • TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LASER PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2023